Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Understand approaches to selecting index funds that minimize taxes in retirement and preserve more of your portfolio.
23,967 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
In a market where mortgage rates wobble and volumes shift, brokerages lean on tech stacks matter, culture to accelera...
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
Sarah Jessica Parker’s journey from a large, struggling family to a $200 million fortune highlights how grit and ambi...
Nvidia is fueling a bold thesis for H2 2026 as AI infrastructure demand climbs. With data-center momentum and locked-...
A market strategist argues the AI urge to spend is cooling, transferring momentum from software giants to chipmakers ...
JPMORGAN Global Research says the AI-related capital spend is not a fleeting hype cycle but a profitable buildout. Th...
Salesforce CRM faces a sharp sell-off even as its AI strategy shows real monetization. Here’s why traders are watchin...
A major insider purchase by BORR's Executive Director has investors buzzing. This article breaks down what the move c...
June brought a tech-focused pullback as Apple raised device prices to offset memory costs. This deep dive explains wh...
A rapid attribution study links this summer’s extreme European heat to human-caused climate change, showing europe wa...
Two iconic beverage players, Coca-Cola and PepsiCo, face different growth paths as 2026 approaches. This article brea...